Redeye makes changes to both the short- and long-term estimates on the back of a very strong quarter...
Redeye endorses yesterday’s news that Idogen has enrolled the first patient in its phase l/lla-trial...
Internal improvements offset by cautious customers Recession risk reflected in update, ‘23e EBIT do...
Ett första steg in i njurtransplantation Guard initierade under slutet av sommaren en fas Ib-studie ...
Redeye remains impressed by the rapid development of Vicore’s new generation of ATRAGs (angiotensin ...
Redeye retains its positive view on Efecte following the Digitalize and Automate 2022 event, with th...
Vår vy är att både bolaget ABAS Protect, och deras stundande notering bjuder på ett intressant läge.
Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to p...
Efter positiva studier från Eisab/Biogen med lecanemab mot Alzheimers sjukdom ser vi att caset för A...
Smart Wires recently announced that it suspended revenue guidance and revised order guidance while s...
We expect a sequential decline in Rovio's Games revenue for Q3 in the midst of mobile gaming market ...
Gross margins to indicate extent of pricing power ’22e-'23e EBIT down 6-5%, while ‘24e EBIT up 8% ...
CirChem meddelade den 10 oktober att de tecknat ännu ett avtal med Stena Recycling, vilket löper öve...
Redeye is encouraged by the positive results from Orexo’s clinical phase I trial with the company’s ...
Förannonserade Q3’22 försäljning och EBIT BE Group förannonserade den 10 oktober 2022 preliminära si...
Series production keeps going strong US dollar boosts sales estimates Equipment pipeline remains e...
Redeye comments on Lifeclean’s decision to appoint David Johansson as the new interim CEO.
Redeye comments on Safeture’s recent orders, including today’s press release connected to its partne...
Analyst Group has entered into an agreement with Brain+ on commissioned research, including Equity R...
C Security Systems: AXA France Approves Spåra
